Progenics Pharmaceuticals Company Profile (NASDAQ:PGNX)

About Progenics Pharmaceuticals

Progenics Pharmaceuticals logoProgenics Pharmaceuticals, Inc. is engaged in developing medicines and other products for targeting and treating cancer. The Company's products in development include therapeutic agents designed to target cancer and imaging agents, which focuses on enabling clinicians and patients to accurately visualize and manage their diseases. The Company's EXINI Bone BSI is an analytical tool that employs an artificial intelligence-based approach to apply techniques of statistical analysis and pattern recognition to quantify the information produced by bone scintigraphy (bone scan) images used to view cancer present in the skeleton. The EXINI Bone BSI tool reads bone scans and produces an automated Bone Scan Index quantification. The Company's clinical-stage products include AZEDRA, 1404 (trofolastat), PyL ([18F] DCFPyL), 1095 and PSMA ADC. The Company's partnered products include Relistor-Subcutaneous injection, Relistor-Oral Tablets and PRO 140.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: PGNX
  • CUSIP: 74318710
Key Metrics:
  • Previous Close: $6.56
  • 50 Day Moving Average: $5.97
  • 200 Day Moving Average: $5.01
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -41.00
  • P/E Growth: 0.18
  • Market Cap: $459.10M
  • Outstanding Shares: 69,985,000
  • Beta: 2.11
Additional Links:
Companies Related to Progenics Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Progenics Pharmaceuticals (NASDAQ:PGNX) (?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $10.75 (63.87% upside)

Analysts' Ratings History for Progenics Pharmaceuticals (NASDAQ:PGNX)
DateFirmActionRatingPrice TargetDetails
8/5/2016Brean CapitalSet Price TargetBuy$14.00View Rating Details
7/22/2016Needham & Company LLCReiterated RatingBuy$11.00View Rating Details
7/20/2016BTIG ResearchReiterated RatingBuy$9.00View Rating Details
6/10/2016Jefferies GroupReiterated RatingBuyView Rating Details
(Data available from 8/25/2014 forward)


Earnings History for Progenics Pharmaceuticals (NASDAQ:PGNX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/4/2016Q216($0.13)($0.08)$6.33 million$8.50 millionViewN/AView Earnings Details
5/5/2016Q116($0.13)($0.18)$3.27 million$2.50 millionViewListenView Earnings Details
3/11/2016Q415($0.14)($0.10)$2.25 million$5.10 millionViewListenView Earnings Details
11/9/2015Q315($0.13)($0.14)$2.35 million$1.40 millionViewListenView Earnings Details
8/6/2015Q215($0.15)($0.17)$1.63 million$1.90 millionViewListenView Earnings Details
5/6/2015Q115($0.16)($0.15)$1.30 million$0.25 millionViewN/AView Earnings Details
3/16/2015Q414($0.13)($0.18)$2.87 million($0.57) millionViewN/AView Earnings Details
11/7/2014Q314($0.16)$0.51$2.50 million$41.66 millionViewN/AView Earnings Details
8/8/2014Q214($0.14)($0.17)$2.83 million$1.50 millionViewListenView Earnings Details
5/9/2014Q114($0.15)($0.15)$2.88 million$1.80 millionViewN/AView Earnings Details
3/13/2014Q4($0.19)($0.14)$1.48 million$3.00 millionViewListenView Earnings Details
11/11/2013Q313($0.22)($0.17)$2.00 million$0.90 millionViewN/AView Earnings Details
8/9/2013Q2 2013($0.24)($0.24)$1.86 million$1.80 millionViewN/AView Earnings Details
5/10/2013Q1 2013($0.19)($0.22)$1.71 million$2.23 millionViewN/AView Earnings Details
3/15/2013Q4 2012($0.31)($0.01)$1.16 million$8.87 millionViewN/AView Earnings Details
11/8/2012Q312($0.30)($0.33)$2.52 million$1.10 millionViewN/AView Earnings Details
8/9/2012($0.32)($0.32)ViewN/AView Earnings Details
5/8/2012($0.33)($0.39)ViewN/AView Earnings Details
11/9/2011($0.33)($0.34)ViewN/AView Earnings Details
8/9/2011($0.25)$1.64ViewN/AView Earnings Details
5/10/2011($0.51)($0.69)ViewN/AView Earnings Details
3/15/2011($0.57)($0.57)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Progenics Pharmaceuticals (NASDAQ:PGNX)
Current Year EPS Consensus Estimate: $0.13 EPS
Next Year EPS Consensus Estimate: $-0.16 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.12)($0.12)($0.12)
Q2 20161($0.11)($0.11)($0.11)
Q3 20161$0.52$0.52$0.52
Q4 20161($0.14)($0.14)($0.14)
(Data provided by Zacks Investment Research)


Dividend History for Progenics Pharmaceuticals (NASDAQ:PGNX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Progenics Pharmaceuticals (NASDAQ:PGNX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/11/2015Robert J IsraelEVPSell2,000$6.83$13,660.00View SEC Filing  
3/13/2015Robert J IsraelEVPSell3,000$7.00$21,000.00View SEC Filing  
3/11/2015Robert J IsraelEVPSell2,000$6.83$13,660.00View SEC Filing  
3/3/2015Robert J IsraelEVPSell5,000$6.49$32,450.00View SEC Filing  
1/12/2015Robert J IsraelEVPSell2,000$7.06$14,120.00View SEC Filing  
12/11/2014Robert J IsraelEVPSell3,000$7.07$21,210.00View SEC Filing  
11/21/2014Robert J IsraelEVPSell9,000$7.00$63,000.00View SEC Filing  
11/13/2014Robert J IsraelEVPSell10,000$6.83$68,300.00View SEC Filing  
11/11/2014Robert J IsraelEVPSell5,000$6.53$32,650.00View SEC Filing  
7/21/2014Healthcare Master Fun BroadfinMajor ShareholderBuy1,625,436$4.60$7,477,005.60View SEC Filing  
7/18/2014Healthcare Master Fun BroadfinMajor ShareholderBuy388,200$4.73$1,836,186.00View SEC Filing  
7/17/2014Healthcare Master Fun BroadfinMajor ShareholderBuy436,884$4.48$1,957,240.32View SEC Filing  
7/16/2014Healthcare Master Fun BroadfinMajor ShareholderBuy411,693$4.48$1,844,384.64View SEC Filing  
7/18/2013Robert J IsraelVPSell5,000$6.33$31,650.00View SEC Filing  
2/27/2013Mark Robert BakerCEOBuy1,262$2.72$3,432.64View SEC Filing  
1/22/2013Mark Robert BakerCEOBuy1,215$2.82$3,426.30View SEC Filing  
12/26/2012Mark Robert BakerCEOBuy1,142$3.01$3,437.42View SEC Filing  
11/28/2012Mark Robert BakerCEOBuy1,607$2.13$3,422.91View SEC Filing  
11/19/2012Mark Robert BakerCEOBuy11,800$1.96$23,128.00View SEC Filing  
11/16/2012Mark Robert BakerCEOBuy49,793$1.82$90,623.26View SEC Filing  
11/15/2012Mark Robert BakerCEOBuy48,833$1.69$82,527.77View SEC Filing  
10/24/2012Mark Robert BakerCEOBuy1,162$2.96$3,439.52View SEC Filing  
9/26/2012Mark Robert BakerCEOBuy1,036$3.32$3,439.52View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Progenics Pharmaceuticals (NASDAQ:PGNX)
News Icon2 Biotech Stocks News And Price Trends: Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), Immunomedics Inc ... - The Voice Registrar (NASDAQ:PGNX) - August 19 at 9:50 AM logo4 Breakout Stocks to Watch This Week (NASDAQ:PGNX) - August 18 at 6:59 PM logoProgenics Pharmaceuticals Shares Up 24.3% Since SmarTrend's Buy Recommendation (PGNX) (NASDAQ:PGNX) - August 17 at 7:05 PM
News IconThe Key Numbers To Watch From Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX)'s Earnings - The Voice Registrar (NASDAQ:PGNX) - August 17 at 9:50 AM logo4 Stocks To Watch: CWEI, EBIO, GIMO, PGNX (NASDAQ:PGNX) - August 16 at 10:04 AM logoPROGENICS PHARMACEUTICALS INC Financials (NASDAQ:PGNX) - August 13 at 6:28 PM logoProgenics Pharmaceuticals Up 21.0% Since SmarTrend Uptrend Call (PGNX) (NASDAQ:PGNX) - August 10 at 7:17 PM
News IconHot Biotech Stocks Recap: Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), Celgene Corporation (NASDAQ:CELG) - The Voice Registrar (NASDAQ:PGNX) - August 10 at 9:55 AM
News IconHealthcare Shares Need To Consider: Progenics Pharmaceuticals ... - TWN (NASDAQ:PGNX) - August 10 at 9:55 AM logoAnalysts Actions to Track: Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) , Merck & Company, Inc. (NYSE:MRK) - Street Updates (NASDAQ:PGNX) - August 10 at 9:55 AM
News IconHigh Volume Healthcare Stocks: Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), Bristol-Myers Squibb Company ... - TWN (NASDAQ:PGNX) - August 10 at 9:55 AM logoWhich way Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) insiders are heading - Review Fortune (NASDAQ:PGNX) - August 10 at 9:55 AM
News IconMost Recent analysts Ratings: Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) - News Oracle (NASDAQ:PGNX) - August 10 at 9:55 AM
News IconProgenics Pharmaceuticals, Inc. (NASDAQ:PGNX): Power of Chart, We Made 15% Profit In Just 2 Weeks (NASDAQ:PGNX) - August 9 at 7:04 PM
News IconAnalyst Stock Ratings: Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), General Electric Company (NYSE:GE) - TWN (NASDAQ:PGNX) - August 6 at 9:36 AM logoProgenics Pharmaceuticals Inc. (PGNX) Jumps 5.9% on August 05 - (NASDAQ:PGNX) - August 6 at 9:36 AM logoValeant’s Relistor Said to Draw Interest of Potential Buyers (NASDAQ:PGNX) - August 5 at 7:01 PM logoProgenics Pharmaceuticals Announces Second Quarter 2016 Financial and Business Results (NASDAQ:PGNX) - August 4 at 7:17 PM logoForm 8-K PROGENICS PHARMACEUTICAL For: Aug 04 (NASDAQ:PGNX) - August 4 at 7:17 PM logoRecent Analysts Ratings of Stocks: Novavax, Inc. (NASDAQ:NVAX) , Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) - Street Updates (NASDAQ:PGNX) - August 4 at 10:00 AM logoProgenics reports 2Q loss (NASDAQ:PGNX) - August 4 at 10:00 AM logoPROGENICS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements (NASDAQ:PGNX) - August 4 at 10:00 AM
News IconHot Biotech Stocks Recap: Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), Geron Corporation (NASDAQ:GERN) - The Voice Registrar (NASDAQ:PGNX) - August 3 at 10:04 AM
News IconPfizer reaches $486 million settlement of Celebrex, Bextra litigation (NASDAQ:PGNX) - August 2 at 7:09 PM logoLatest Analysts Tips Update: Anavex Life Sciences Corp (NASDAQ:AVXL) , Progenics Pharmaceuticals Inc. (NASDAQ ... - Street Updates (NASDAQ:PGNX) - July 29 at 9:51 AM
News IconEarnings Trend of the Stocks: Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), Aaron's, Inc. (NYSE:AAN) - News Oracle (NASDAQ:PGNX) - July 29 at 9:51 AM
News IconProgenics Receives $50 Million Milestone Payment Following FDA Approval of RELISTOR® Tablets for the Treatment of Opioid-Induced Constipation in… (NASDAQ:PGNX) - July 28 at 10:01 AM logoLooking At Recent Analyst Ratings: Amkor Technology, Inc. (NASDAQ:AMKR), Progenics Pharmaceuticals, Inc ... - Review Fortune (NASDAQ:PGNX) - July 27 at 9:51 AM logoProgenics Pharma (PGNX) Receives Milestone Payment Tied to FDA Approval of RELISTOR (VRX) - (NASDAQ:PGNX) - July 27 at 9:51 AM logoProgenics Pharma (PGNX) Receives Milestone Payment Tied to FDA Approval of RELISTOR (VRX) (NASDAQ:PGNX) - July 26 at 7:09 PM logoCompany Eligible to Receive Up to $200 Million of Sales Milestone Payments and Ongoing Sales Royalties (NASDAQ:PGNX) - July 26 at 10:05 AM logoProgenics Receives $50 Million Milestone Payment Following FDA Approval of RELISTOR® Tablets for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-cancer Pain (NASDAQ:PGNX) - July 26 at 8:58 AM logoProgenics receives $50 mln milestone payment after opioid-induced constipation drug approval (NASDAQ:PGNX) - July 26 at 8:37 AM logoTrader's Round Up: The Western Union Company (WU), Progenics Pharmaceuticals, Inc. (PGNX), VMware, Inc. (VMW) - iStreetWire (NASDAQ:PGNX) - July 25 at 6:59 PM logoAmerican Electric Power Company Inc (NYSE:AEP) & , Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) Stocks Alert - Wall Street 24 (NASDAQ:PGNX) - July 25 at 11:13 AM logoAnalysts Rating Overview: Stryker Corporation (NYSE:SYK) , Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) - Street Updates (NASDAQ:PGNX) - July 25 at 11:13 AM logoLatest Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) Target Price Suggests Stock Is Worth $10.75/Share - Review Fortune (NASDAQ:PGNX) - July 25 at 11:13 AM logoCan Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) Surprise Analysts this Quarter? - Investor Newswire (NASDAQ:PGNX) - July 23 at 6:19 PM logoProgenics Pharmaceuticals Inc. (PGNX) is Trading Higher on Unusual Volume for July 20 - (NASDAQ:PGNX) - July 23 at 6:19 PM
News IconBBP: An Outperforming Biotechnology ETF (NASDAQ:PGNX) - July 22 at 9:46 AM logoProgenics Pharmaceuticals Sets Second Quarter 2016 Financial Results Call for August 4 (NASDAQ:PGNX) - July 22 at 8:48 AM logoETF’s with exposure to Progenics Pharmaceuticals, Inc. : July 21, 2016 (NASDAQ:PGNX) - July 21 at 2:22 PM logoBrean Capital Sees 125% Upside for Progenics Pharmaceuticals, Inc. (PGNX) Following FDA Approval for Oral Relistor - Smarter Analyst (NASDAQ:PGNX) - July 21 at 9:41 AM logoProgenics Pharmaceuticals Inc. (PGNX) Jumps 24.29% on July 20 - (NASDAQ:PGNX) - July 21 at 9:41 AM
News IconAnalyst Consideration on this Stock: Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) - News Oracle (NASDAQ:PGNX) - July 21 at 9:41 AM logoOptions Volume Explodes as Progenics Pharmaceuticals, Inc. (PGNX) Takes Off - Schaeffers Research (blog) (NASDAQ:PGNX) - July 21 at 9:41 AM logoValeant Pharma (VRX), Progenics Pharmaceuticals (PGNX) Granted FDA Approval for RELISTOR (NASDAQ:PGNX) - July 20 at 7:38 PM
News IconProgenics Pharmaceuticals, Inc. (NASDAQ:PGNX): Our Members Are Already Up 25% In Very Quick Time (NASDAQ:PGNX) - July 20 at 7:38 PM logoOptions Volume Explodes as Progenics Pharmaceuticals, Inc. (PGNX) Takes Off (NASDAQ:PGNX) - July 20 at 7:38 PM logoWhy Progenics Pharmaceuticals, Inc. Shares Soared Today (NASDAQ:PGNX) - July 20 at 4:31 PM


Progenics Pharmaceuticals (NASDAQ:PGNX) Chart for Thursday, August, 25, 2016

Last Updated on 8/25/2016 by Staff